The emerging field of osteoimmunology

[1]  Y. Toyama,et al.  The role of DC-STAMP in maintenance of immune tolerance through regulation of dendritic cell function. , 2008, International immunology.

[2]  A. Mandelin,et al.  TH-17 cells in rheumatoid arthritis , 2008, Arthritis research & therapy.

[3]  Chen Dong,et al.  TH17 cells in development: an updated view of their molecular identity and genetic programming , 2008, Nature Reviews Immunology.

[4]  Jay K Kolls,et al.  The Biological Functions of T Helper 17 Cell Effector Cytokines in Inflammation , 2022 .

[5]  J. Smolen,et al.  CTLA-4 directly inhibits osteoclast formation , 2008, Annals of the rheumatic diseases.

[6]  R. Matthews.  The B Cell Slayer , 2007, Science.

[7]  A. Paradowska,et al.  The function of interleukin 17 in the pathogenesis of rheumatoid arthritis , 2007, Archivum Immunologiae et Therapiae Experimentalis.

[8]  D. Mosser,et al.  Monocyte subpopulations and their differentiation patterns during infection , 2007, Journal of leukocyte biology.

[9]  D. Gladman,et al.  Infliximab inhibits progression of radiographic damage in patients with active psoriatic arthritis through one year of treatment: Results from the induction and maintenance psoriatic arthritis clinical trial 2. , 2007, Arthritis and rheumatism.

[10]  E. Schwarz,et al.  Clinical development of anti-RANKL therapy , 2007, Arthritis research & therapy.

[11]  Elizabeth H. Chen,et al.  Cell–cell fusion , 2007, FEBS letters.

[12]  Wei-Ping Qian,et al.  B cells and T cells are critical for the preservation of bone homeostasis and attainment of peak bone mass in vivo. , 2007, Blood.

[13]  H. Takayanagi.  Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems , 2007, Nature Reviews Immunology.

[14]  L. Ziegler‐Heitbrock,et al.  The CD14+ CD16+ blood monocytes: their role in infection and inflammation , 2007, Journal of leukocyte biology.

[15]  S. Teitelbaum.  Osteoclasts: what do they do and how do they do it? , 2007, The American journal of pathology.

[16]  Georg Schett,et al.  Dickkopf-1 is a master regulator of joint remodeling , 2007, Nature Medicine.

[17]  T. Miyamoto.  The dendritic cell-specific transmembrane protein DC-STAMP is essential for osteoclast fusion and osteoclast bone-resorbing activity , 2006, Modern rheumatology.

[18]  Stanley B. Cohen,et al.  Rituximab for rheumatoid arthritis refractory to anti-tumor necrosis factor therapy: Results of a multicenter, randomized, double-blind, placebo-controlled, phase III trial evaluating primary efficacy and safety at twenty-four weeks. , 2006, Arthritis and rheumatism.

[19]  Y. Kadono,et al.  Osteoimmunology: interplay between the immune system and bone metabolism. , 2006, Annual review of immunology.

[20]  P. Miller,et al.  Denosumab in Postmenopausal Women with Low Bone Mineral Density , 2007 .

[21]  S. Gordon,et al.  Monocyte and macrophage heterogeneity , 2005, Nature Reviews Immunology.

[22]  R. D. Hatton,et al.  Interleukin 17–producing CD4+ effector T cells develop via a lineage distinct from the T helper type 1 and 2 lineages , 2005, Nature Immunology.

[23]  D. Gladman,et al.  Adalimumab for the treatment of patients with moderately to severely active psoriatic arthritis: results of a double-blind, randomized, placebo-controlled trial. , 2005, Arthritis and rheumatism.

[24]  Y. Toyama,et al.  DC-STAMP is essential for cell–cell fusion in osteoclasts and foreign body giant cells , 2005, The Journal of experimental medicine.

[25]  F. Luyten,et al.  Modulation of bone morphogenetic protein signaling inhibits the onset and progression of ankylosing enthesitis. , 2005, The Journal of clinical investigation.

[26]  C. Rabourdin-Combe,et al.  Immature dendritic cell transdifferentiation into osteoclasts: a novel pathway sustained by the rheumatoid arthritis microenvironment. , 2004, Blood.

[27]  K. Toh,et al.  RANKL-induced DC-STAMP Is Essential for Osteoclastogenesis , 2004, The Journal of experimental medicine.

[28]  J. Smolen,et al.  Arthritis Induces Lymphocytic Bone Marrow Inflammation and Endosteal Bone Formation , 2004 .

[29]  M. Duddy,et al.  Distinct Profiles of Human B Cell Effector Cytokines: A Role in Immune Regulation?1 , 2004, The Journal of Immunology.

[30]  M. Takami,et al.  Osteoimmunology: interactions of the immune and skeletal systems. , 2004, Molecules and Cells.

[31]  D. Scadden,et al.  Osteoblastic cells regulate the haematopoietic stem cell niche , 2003, Nature.

[32]  A. Keegan,et al.  IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL. , 2003, Blood.

[33]  David L. Lacey,et al.  Osteoclast differentiation and activation , 2003, Nature.

[34]  E. Lubberts.  The role of IL-17 and family members in the pathogenesis of arthritis. , 2003, Current opinion in investigational drugs.

[35]  J. Bijlsma,et al.  Fcγ receptor expression levels on monocytes are elevated in rheumatoid arthritis patients with high erythrocyte sedimentation rate who do not use anti‐rheumatic drugs , 2003 .

[36]  E. Schwarz,et al.  Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. , 2003, The Journal of clinical investigation.

[37]  W. Dougall,et al.  A RANK/TRAF6-dependent Signal Transduction Pathway Is Essential for Osteoclast Cytoskeletal Organization and Resorptive Function* , 2002, The Journal of Biological Chemistry.

[38]  J. Penninger,et al.  Role of RANKL and RANK in bone loss and arthritis , 2002, Annals of the rheumatic diseases.

[39]  J. Edwards.  Importance of T cells in rheumatoid synovitis: comment on the review by Firestein and Zvaifler. , 2002, Arthritis and rheumatism.

[40]  H. Makino,et al.  CD14+,CD16+ blood monocytes and joint inflammation in rheumatoid arthritis. , 2002, Arthritis and rheumatism.

[41]  Hao Wu,et al.  Distinct molecular mechanism for initiating TRAF6 signalling , 2002, Nature.

[42]  S. Nishikawa,et al.  TRAF6-deficient mice display hypohidrotic ectodermal dysplasia , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[43]  J. Smolen,et al.  Autoantibodies in rheumatoid arthritis and their clinical significance. , 2002, Arthritis research.

[44]  B. Kirkham,et al.  Reduction of joint inflammation and bone erosion in rat adjuvant arthritis by treatment with interleukin-17 receptor IgG1 Fc fusion protein. , 2002, Arthritis and rheumatism.

[45]  T. Suda,et al.  Bifurcation of osteoclasts and dendritic cells from common progenitors. , 2001, Blood.

[46]  Y. Abu-Amer.  IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-κB , 2001 .

[47]  J. Reginster,et al.  Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis. , 2001, The New England journal of medicine.

[48]  Y. Kadono,et al.  Segregation of TRAF6‐mediated signaling pathways clarifies its role in osteoclastogenesis , 2001, The EMBO journal.

[49]  H. Staege,et al.  Two novel genes FIND and LIND differentially expressed in deactivated and Listeria-infected human macrophages , 2001, Immunogenetics.

[50]  A. Nakanishi,et al.  The Effect of a Single Dose of Osteoprotegerin in Postmenopausal Women , 2001, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[51]  R. Baron,et al.  Activated parathyroid hormone/parathyroid hormone-related protein receptor in osteoblastic cells differentially affects cortical and trabecular bone. , 2001, The Journal of clinical investigation.

[52]  C. Figdor,et al.  DC‐STAMP, a novel multimembrane‐spanning molecule preferentially expressed by dendritic cells , 2000, European journal of immunology.

[53]  T. Martin,et al.  Therapeutic approaches to bone diseases. , 2000, Science.

[54]  S. Takeshita,et al.  Identification and Characterization of the New Osteoclast Progenitor with Macrophage Phenotypes Being Able to Differentiate into Mature Osteoclasts , 2000, Journal of bone and mineral research : the official journal of the American Society for Bone and Mineral Research.

[55]  T. Komori,et al.  Regulation of osteoblast differentiation mediated by bone morphogenetic proteins, hedgehogs, and Cbfa1. , 2000, Endocrine reviews.

[56]  T. Miyata,et al.  Commitment and Differentiation of Osteoclast Precursor Cells by the Sequential Expression of C-Fms and Receptor Activator of Nuclear Factor κb (Rank) Receptors , 1999, The Journal of experimental medicine.

[57]  H. Hanafusa,et al.  TRANCE, a TNF family member, activates Akt/PKB through a signaling complex involving TRAF6 and c-Src. , 1999, Molecular cell.

[58]  Josef M. Penninger,et al.  Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand , 1999, Nature.

[59]  Yongwon Choi,et al.  TRANCE is a TNF family member that regulates dendritic cell and osteoclast function , 1999, Journal of leukocyte biology.

[60]  P. Miossec,et al.  Human interleukin-17: A T cell-derived proinflammatory cytokine produced by the rheumatoid synovium. , 1999, Arthritis and rheumatism.

[61]  T. Martin,et al.  IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis. , 1999, The Journal of clinical investigation.

[62]  S. Morony,et al.  TRAF6 deficiency results in osteopetrosis and defective interleukin-1, CD40, and LPS signaling. , 1999, Genes & development.

[63]  B. Kwon,et al.  Receptor activator of NF‐κB recruits multiple TRAF family adaptors and activates c‐Jun N‐terminal kinase , 1999, FEBS letters.

[64]  G. Kollias,et al.  Mice lacking mature T and B lymphocytes develop arthritic lesions after immunization with type II collagen. , 1999, Journal of immunology.

[65]  A. Livolsi,et al.  Tumor Necrosis Factor-α Activation of Nuclear Transcription Factor-κB in Marrow Macrophages Is Mediated by c-Src Tyrosine Phosphorylation of IκBα* , 1998, The Journal of Biological Chemistry.

[66]  D. Lacey,et al.  Osteoprotegerin Ligand Is a Cytokine that Regulates Osteoclast Differentiation and Activation , 1998, Cell.

[67]  K Yano,et al.  Osteoclast differentiation factor is a ligand for osteoprotegerin/osteoclastogenesis-inhibitory factor and is identical to TRANCE/RANKL. , 1998, Proceedings of the National Academy of Sciences of the United States of America.

[68]  R. Steinman,et al.  TRANCE (Tumor Necrosis Factor [TNF]-related Activation-induced Cytokine), a New TNF Family Member Predominantly Expressed in T cells, Is a Dendritic Cell–specific Survival Factor , 1997, The Journal of experimental medicine.

[69]  R. Dubose,et al.  A homologue of the TNF receptor and its ligand enhance T-cell growth and dendritic-cell function , 1997, Nature.

[70]  G Shimamoto,et al.  Osteoprotegerin: A Novel Secreted Protein Involved in the Regulation of Bone Density , 1997, Cell.

[71]  D. Kioussis,et al.  Transgenic mice expressing human tumour necrosis factor: a predictive genetic model of arthritis. , 1991, The EMBO journal.

[72]  A. Cope,et al.  Regulatory T cells suppress osteoclast formation: A new link between the immune system and bone , 2008 .

[73]  J. Block,et al.  Rheumatoid arthritis: beyond tumor necrosis factor-alpha antagonists, B cell depletion, and T cell blockade. , 2008, American journal of therapeutics.

[74]  R. Matthews.  Autoimmune diseases. The B cell slayer. , 2007, Science.

[75]  Y. Toyama,et al.  Role of DC-STAMP in cellular fusion of osteoclasts and macrophage giant cells , 2006, Journal of Bone and Mineral Metabolism.

[76]  Y. Yazici,et al.  Denosumab in postmenopausal women with low bone mineral density. , 2006, The New England journal of medicine.

[77]  E. Schwarz,et al.  Systemic tumor necrosis factor α mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor α–transgenic mice , 2004 .

[78]  E. Schwarz,et al.  Systemic tumor necrosis factor alpha mediates an increase in peripheral CD11bhigh osteoclast precursors in tumor necrosis factor alpha-transgenic mice. , 2004, Arthritis and rheumatism.

[79]  J. Bijlsma,et al.  Fcgamma receptor expression levels on monocytes are elevated in rheumatoid arthritis patients with high erythrocyte sedimentation rate who do not use anti-rheumatic drugs. , 2003, Rheumatology.

[80]  E. Schwarz,et al.  The TNF-alpha transgenic mouse model of inflammatory arthritis. , 2003, Springer seminars in immunopathology.

[81]  S. Takemura.  Lymphoid neogenesis in rheumatoid synovitis , 2003 .

[82]  Y. Abu-Amer.  IL-4 abrogates osteoclastogenesis through STAT6-dependent inhibition of NF-kappaB. , 2001, The Journal of clinical investigation.

[83]  Josef M. Penninger,et al.  Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand , 1999, Nature.

[84]  A. Livolsi,et al.  Tumor necrosis factor-alpha activation of nuclear transcription factor-kappaB in marrow macrophages is mediated by c-Src tyrosine phosphorylation of Ikappa Balpha. , 1998, The Journal of biological chemistry.